

AMENDMENTS TO THE CLAIMS

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-31. (Cancelled)

32. (New) An oily pharmaceutical composition comprising a therapeutically effective amount of etonogestrel undecanoate and/or etonogestrel decanoate and/or etonogestrel dodecanoate.

33. (New) The pharmaceutical composition according to claim 32, further comprising a therapeutically effective amount of an androgen ester.

34. (New) The pharmaceutical composition according to claim 32, further comprising a therapeutically effective amount of an estrogen.

35. (New) The pharmaceutical composition according to claim 33, wherein the androgen ester is MENT undecanoate.

36. (New) The pharmaceutical composition according to claim 35, wherein the amount of MENT undecanoate is 50-400 mg and the amount of etonogestrel undecanoate and/or etonogestrel decanoate and/or etonogestrel dodecanoate is 25-200 mg.

37. (New) A method for contraception and/or hormone replacement therapy, the method comprising administering to a subject by injection a therapeutically effective amount of etonogestrel undecanoate and/or etonogestrel decanoate and/or etonogestrel dodecanoate, wherein the etonogestrel undecanoate and/or etonogestrel decanoate and/or etonogestrel dodecanoate is contained in an oily medium.

38. (New) The method according to claim 37, wherein the etonogestrel undecanoate and/or etonogestrel decanoate and/or etonogestrel dodecanoate is administered in conjunction with a therapeutically effective amount of an estrogen.

39. (New) A method for male contraception and/or male hormone replacement therapy, the method comprising administering to a subject a therapeutically effective amount of a etonogestrel undecanoate and/or etonogestrel decanoate and/or etonogestrel dodecanoate, in conjunction with a therapeutically effective long-acting androgen ester.

40. (New) The method according to claim 39, wherein the long-acting ester is MENT undecanoate.

41. (New) The method according to claim 40, wherein the therapeutically effective amount of MENT undecanoate is 50-400 mg and the therapeutically effective amount of etonogestrel undecanoate and/or etonogestrel decanoate and/or etonogestrel dodecanoate is 25-200 mg.